24/7 Market News Snapshot 28 March, 2025 – Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

March 28, 2025

DENVER, Colo., 28 March, 2025 (247marketnews.com) – (NASDAQ:LXRX) are discussed in this article.
Lexicon Pharmaceuticals, Inc. (LXRX) is experiencing a remarkable surge in the pre-market trading session, with shares climbing to $0.669—an increase of 92.46% from the prior close of $0.348. The stock has seen an impressive trading volume, reaching 8.17 million shares, indicating a robust interest among investors and a positive sentiment surrounding the company’s prospects.

In a pivotal move to bolster its position in the market, Lexicon Pharmaceuticals has entered a strategic licensing agreement with Novo Nordisk A/S for LX9851, an innovative oral candidate aimed at addressing obesity and metabolic disorders. This exclusive agreement grants Novo Nordisk global rights to develop, manufacture, and commercialize LX9851 across all applications. Lexicon will complete the necessary Investigational New Drug (IND) application-enabling processes, while Novo Nordisk will undertake the IND filing and manage subsequent development and commercialization efforts. The partnership could generate up to $1 billion for Lexicon through upfront payments and milestones, in addition to tiered royalties based on net sales.

The candidate, LX9851, is distinguished as a first-in-class small molecule that selectively inhibits Acyl-CoA Synthetase 5 (ACSL5), a crucial component in the metabolic pathways that regulate fat accumulation and energy balance. Preclinical data presented at Obesity Week 2024 underscored the efficacy of LX9851, indicating significant weight loss, appetite suppression, and fat mass reduction, especially when used in conjunction with semaglutide.

Mike Exton, Ph.D., CEO of Lexicon, expressed enthusiasm regarding the collaboration, highlighting its potential to enhance the company’s financial stability and expand its research and development portfolio. Jacob Sten Petersen, Senior Vice President at Novo Nordisk, reiterated the importance of the partnership in exploring new biological pathways for treatment, further solidifying both companies’ commitment to addressing the rising challenges of obesity and metabolic disorders.

Related news for (LXRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.